{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:34:24Z","timestamp":1754487264445,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The effectiveness of Crohn\u2019s disease treatments for inducing histological outcomes has not been addressed systematically. We performed a systematic review and meta-analysis of randomized controlled trials in Crohn\u2019s disease to assess the impact of therapies on mucosal histopathology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Databases (MEDLINE, CENTRAL, Web of Science, EMBASE) were searched for randomized controlled trials including adult patients and evaluating histological outcomes. Risk of bias was evaluated using the Critical Appraisal Skills Programme. Histological outcomes, pooled frequencies, pooled odds ratios, and standard mean differences of the histological scores were compared between the intervention and placebo groups using a random-effects model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 2070 records, 10 studies were included. The quality of the studies ranged from moderate to high, but they were clinically and methodologically diverse. All interventions were superior to placebo. Histological response was achieved by 68% of patients, and 38% achieved remission. Pooled odds ratio for histological remission in patients receiving intervention vs placebo was 4.14 (95% CI, 2.28-7.50; I2 0%; P &amp;lt; .01). Heterogeneity in histological response estimates was significant, and subgroup analysis of the odds ratio results was limited by the low number of studies per group. The standard mean difference of histological scores was higher for patients receiving intervention in both induction and maintenance studies (\u22122.95; 95% CI, \u22124.17 to \u22121.74; I2 83% P &amp;lt; .00; and \u22122.58; 95% CI, \u22123.89 to \u22121.27; I2 56% P &amp;lt; .00).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Crohn\u2019s disease therapies are effective for achieving histological outcomes. Adherence to recently published consensus on histopathology harmonization assessment in Crohn\u2019s disease would facilitate adequate comparison between studies in the future.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ibd\/izac203","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T18:36:48Z","timestamp":1666031808000},"page":"1231-1243","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Crohn\u2019s Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5098-8729","authenticated-orcid":false,"given":"Joana","family":"Roseira","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Algarve University Hospital Center , Faro , Portugal"},{"name":"ABC (Algarve Biomedical Center) , Loul\u00e9 , Portugal"}]},{"given":"Mafalda","family":"Santiago","sequence":"additional","affiliation":[{"name":"CINTESIS (Centro de Investiga\u00e7\u00e3o em Tecnologias e Servi\u00e7os de Sa\u00fade) , Porto , Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-0139","authenticated-orcid":false,"given":"Maria Manuela","family":"Estevinho","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Gaia\/Espinho Hospital Center , Gaia\/Espinho , Portugal"},{"name":"Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto , Porto , Portugal"}]},{"given":"Paula","family":"Moreira","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, S\u00e3o Jo\u00e3o Hospital University Center , Porto , Portugal"}]},{"given":"Catarina","family":"Alves","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Porto , Porto , Portugal"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele , Milan , Italy"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine , Nancy , France"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Agaplesion Markus Hospital, Goethe-University , Frankfurt am Main , Germany"}]},{"given":"Roger","family":"Feakins","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Royal Free Hospital, London, and University College London , UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto , Porto , Portugal"},{"name":"Faculty of Medicine, University of Porto , Porto , Portugal"},{"name":"Department of Gastroenterology, S\u00e3o Jo\u00e3o Hospital Center , Porto , Portugal"},{"name":"MedInUP, Center for Drug Discovery and Innovative Medicines , Porto , Portugal"}]}],"member":"286","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"issue":"12","key":"2023080117200963000_CIT0001","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2023080117200963000_CIT0002","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/ecco-jcc\/jjaa176","article-title":"Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis","volume":"15","author":"Magro","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2023080117200963000_CIT0003","first-page":"1800","article-title":"Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"19","author":"Gupta","year":"2021","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"5","key":"2023080117200963000_CIT0004","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"2023080117200963000_CIT0005","article-title":"Histologic scoring indices for evaluation of disease activity in Crohn\u2019s disease","author":"Novak","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2023080117200963000_CIT0006","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/apt.16248","article-title":"An expert consensus to standardise the assessment of histological disease activity in Crohn\u2019s disease clinical trials","volume":"53","author":"Almradi","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"2023080117200963000_CIT0007","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac006","article-title":"ECCO position on harmonization of Crohn\u2019s disease mucosal histopathology","author":"Magro","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2023080117200963000_CIT0008","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg."},{"key":"2023080117200963000_CIT0009","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"The Cochrane database of systematic reviews"},{"author":"Critical Appraisal Skills Programme","key":"2023080117200963000_CIT0010"},{"year":"2013","author":"Altman","key":"2023080117200963000_CIT0011"},{"issue":"11","key":"2023080117200963000_CIT0012","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1185\/030079905X65457","article-title":"Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn\u2019s disease","volume":"21","author":"Geboes","year":"2005","journal-title":"Curr Med Res Opin."},{"year":"2021","author":"Pai","key":"2023080117200963000_CIT0013"},{"issue":"5","key":"2023080117200963000_CIT0014","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: A European multicenter trial","volume":"116","author":"D\u2019haens","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"2023080117200963000_CIT0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn\u2019s ileocolitis","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology"},{"issue":"7","key":"2023080117200963000_CIT0016","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","article-title":"Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial","volume":"56","author":"Smith","year":"2011","journal-title":"Dig Dis Sci."},{"issue":"10066","key":"2023080117200963000_CIT0017","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2023080117200963000_CIT0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/ecco-jcc\/jjw143","article-title":"Phase 1 clinical study of siRNA targeting carbohydrate sulphotransferase 15 in Crohn\u2019s disease patients with active mucosal lesions","volume":"11","author":"Suzuki","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2023080117200963000_CIT0019","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ibd.20777","article-title":"Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn\u2019s disease","volume":"15","author":"Mantzaris","year":"2009","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2023080117200963000_CIT0020","first-page":"425","article-title":"Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn\u2019s Disease: results from the EXTEND trial","volume":"11","author":"Reinisch","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2023080117200963000_CIT0021","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1365-2036.2010.04417.x","article-title":"Clinical trial: the microbiological and immunological effects of synbiotic consumption-a randomized double-blind placebo-controlled study in active Crohn\u2019s disease","volume":"32","author":"Steed","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2023080117200963000_CIT0022","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1053\/j.gastro.2019.06.037","article-title":"Effects of ustekinumab on histologic disease activity in patients with Crohn\u2019s disease","volume":"157","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"2023080117200963000_CIT0023","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.1998.00728.x","article-title":"Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines","volume":"114","author":"Dieleman","year":"1998","journal-title":"Clin Exp Immunol."},{"issue":"1","key":"2023080117200963000_CIT0024","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.gastro.2005.05.019","article-title":"Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation","volume":"129","author":"Theiss","year":"2005","journal-title":"Gastroenterology"},{"issue":"9","key":"2023080117200963000_CIT0025","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.crohns.2012.10.018","article-title":"Achievement of deep remission during scheduled maintenance therapy with TNF\u03b1-blocking agents in IBD","volume":"7","author":"Molander","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"2","key":"2023080117200963000_CIT0026","doi-asserted-by":"crossref","first-page":"362 LP","DOI":"10.1136\/gutjnl-2016-312673","article-title":"Recent advances in clinical practice: a systematic review of isolated colonic Crohn\u2019s disease: the third IBD","volume":"66","author":"Subramanian","year":"2017","journal-title":"Gut"},{"issue":"4","key":"2023080117200963000_CIT0027","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2023080117200963000_CIT0028","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","article-title":"Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn\u2019s disease","volume":"157","author":"Danese","year":"2019","journal-title":"Gastroenterology"},{"issue":"13","key":"2023080117200963000_CIT0029","first-page":"2634","article-title":"Should we divide Crohn\u2019s disease into ileum-dominant and isolated colonic diseases","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"2023080117200963000_CIT0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.grj.2015.02.004","article-title":"When are old data new data","volume":"6","author":"Elizabeth Griffin","year":"2015","journal-title":"GeoResJ"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac203\/46544443\/izac203.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/8\/1231\/51017540\/izac203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/8\/1231\/51017540\/izac203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:50:26Z","timestamp":1701219026000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/8\/1231\/6762046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac203","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2022,10,17]]}}}